Anti-bacterial vaccine compositions with a mutated yleA gene
View Patent ↗Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
1. An isolated, attenuated Pasteurella multocida bacterium comprising a mutation in a polynucleotide sequence that encodes the yleA polypeptide of SEQ ID NO: 81, wherein said mutation results in a mutated yleA polypeptide.
2. The bacterium of claim 1 , wherein the mutation results in deletion of all or part of the polynucleotide sequence that encodes the yleA polypeptide.
3. The bacterium of claim 1 , wherein the mutation results in an insertion in the polynucleotide sequence that encodes the yleA polypeptide.
4. An immunogenic composition comprising the bacterium according to claim 1 .
5. A vaccine composition comprising the immunogenic composition according to claim 4 and a pharmaceutically acceptable carrier.
6. The vaccine composition according to claim 5 , further comprising an adjuvant.
7. An isolated, attenuated Pasteurella multocida bacterium comprising a mutation in a polynucleotide sequence that encodes a yleA polypeptide, wherein the polynucleotide sequence hybridizes to the complement of the polynucleotide sequence set forth in SEQ ID NO: 80 under stringent conditions, said stringent conditions comprising a final wash in buffer comprising 2×SSC/0.1% SDS, at 65° C. to 75° C., wherein the mutation is in the polynucleotide sequence set forth in SEQ ID NO: 80.
8. An immunogenic composition comprising the bacterium according to claim 7 .
9. A vaccine composition comprising the immunogenic composition according to claim 8 and a pharmaceutically acceptable carrier.
10. The vaccine composition of claim 9 , further comprising an adjuvant.